SCHEMBL5778971

SCHEMBL5778971

C(=NNc1ccc(-c2cnco2)cc1)c1ccc[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
KMT2A Q03164 3/20 0.50
GAA P10253 2/20 0.50
MEN1 O00255 2/20 0.50
PSMD14 O00487 1/20 0.50
MMP2 P08253 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
NFKB1 P19838 1/20 0.50
BLM P54132 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PKM P14618 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5778806 0.79 NOX1 (0.54) LMNAKMT2AGAAMEN1HPGD
SCHEMBL5778811 0.79 NOX1 (0.54) LMNAKMT2AGAAMEN1HPGD
SCHEMBL5775495 0.79 PTK2 (0.41) LMNAKMT2AGAAMEN1PKM
SCHEMBL5779703 0.77 GAA (0.42) LMNAKMT2AGAAMEN1SMN1; SMN2
SCHEMBL5779700 0.77 GAA (0.42) LMNAKMT2AGAAMEN1SMN1; SMN2
SCHEMBL14742652 0.76 RAB9A (0.55) LMNAKMT2AGAAMEN1SMN1; SMN2
SCHEMBL5776228 0.76 RAB9A (0.55) LMNAKMT2AGAAMEN1SMN1; SMN2
SCHEMBL5776531 0.76 MAPT (0.61) LMNAKMT2AGAAMEN1SMN1; SMN2
Hydrochloric Acid SCHEMBL5778200 0.75 RAB9A (0.57) LMNAKMT2AGAAMEN1SMN1; SMN2
SCHEMBL5777482 0.75 KDM4E (0.47) LMNAKMT2AGAASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT LMNA 861/4885KMT2A 3533/4885GAA 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.